EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600–Mutant Pediatric High-Grade Glioma

Darren R Hargrave iD, Keita Terashima, Junichi Hara iD, Uwe R Kordes iD, Santhosh A Upadhyaya iD, Felix Sahm iD, Eric Bouffet iD, Roger J Packer, Olaf Witt, Larissa Sandalic, Agnieszka Kieloch, Mark Russo iD und 2 weitere

Journal of Clinical Oncology · 20.11.2023 · 41 (33) · 5174-5183

DOI: 10.1200/jco.23.00558 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2023. Verfasst von Darren R Hargrave und 13 weiteren Autor:innen. Beteiligte Einrichtung: UCL Great Ormond Street Institute of Child Health, London, United Kingdom. Hauptthemen laut MEDLINE: Melanoma, Glioma. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE BRAF V600 mutation is detected in 5%-10% of pediatric high-grade gliomas (pHGGs), and effective treatments are limited. In previous trials, dabrafenib as monotherapy or in combination with trametinib demonstrated activity in children and adults with relapsed/refractory BRAF V600–mutant HGG. METHODS This phase II study evaluated dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600–mutant pHGG. The primary objective was overall response rate (ORR) by independent review by Response Assessment in Neuro-Oncology criteria. Secondary objectives included ORR by investigator determination, duration of response (DOR), progression-free survival, overall survival (OS), and safety. RESULTS A total of 41 pediatric patients with previously treated BRAF V600–mutant HGG were enrolled. At primary analysis, median follow-up was 25.1 months, and 51% of patients remained on treatment. Sixteen of 20 discontinuations were due to progressive disease in this relapsed/refractory pHGG population. Independently assessed ORR was 56% (95% CI, 40 to 72). Median DOR was 22.2 months (95% CI, 7.6 months to not reached [NR]). Fourteen deaths were reported. Median OS was 32.8 months (95% CI, 19.2 months to NR). The most common all-cause adverse events (AEs) were pyrexia (51%), headache (34%), and dry skin (32%). Two patients (5%) had AEs (both rash) leading to discontinuation. CONCLUSION In relapsed/refractory BRAF V600–mutant pHGG, dabrafenib plus trametinib improved ORR versus previous trials of chemotherapy in molecularly unselected patients with pHGG and was associated with durable responses and encouraging survival. These findings suggest that dabrafenib plus trametinib is a promising targeted therapy option for children and adolescents with relapsed/refractory BRAF V600–mutant HGG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaGliomaAdultAdolescentHumansChildProto-Oncogene Proteins B-rafOximesPyridonesPyrimidinonesAntineoplastic Combined Chemotherapy ProtocolsMutationImidazoles

Substanzen

Proto-Oncogene Proteins B-rafOximesPyridonesPyrimidinonesdabrafenibImidazolestrametinibBRAF protein, human

Autor:innen und Institutionen

  • UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
  • National Center for Child Health and Development, Tokyo, Japan.
  • Osaka City General Hospital, Osaka, Japan.
  • University Medical Center Eppendorf, Hamburg, Germany.
  • Department of Oncology, St Jude Children's Research Hospital, Memphis, TN.
  • Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.

ORCID-Profile: Darren R Hargrave, Junichi Hara, Uwe R Kordes, Santhosh A Upadhyaya, Felix Sahm, Eric Bouffet, Mark Russo, Kenneth J Cohen

Zitieren

APA

Hargrave, D. R., Terashima, K., Hara, J., Kordes, U. R., Upadhyaya, S. A., Sahm, F., Bouffet, E., Packer, R. J., Witt, O., Sandalic, L., Kieloch, A., Russo, M., Cohen, K. J., & Investigators involved in the high-grade glioma cohort (2023). Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600–Mutant Pediatric High-Grade Glioma. Journal of Clinical Oncology, 41(33), 5174-5183. https://doi.org/10.1200/jco.23.00558

Vancouver

Hargrave DR, Terashima K, Hara J, Kordes UR, Upadhyaya SA, Sahm F, et al. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600–Mutant Pediatric High-Grade Glioma. Journal of Clinical Oncology. 2023;41(33):5174-5183. doi:10.1200/jco.23.00558

BibTeX
@article{Hargrave2023,
  author = {Hargrave, Darren R and Terashima, Keita and Hara, Junichi and Kordes, Uwe R and Upadhyaya, Santhosh A and Sahm, Felix and Bouffet, Eric and Packer, Roger J and Witt, Olaf and Sandalic, Larissa and Kieloch, Agnieszka and Russo, Mark and Cohen, Kenneth J and Investigators involved in the high-grade glioma cohort, Investigators involved in the high-grade glioma cohort},
  title = {Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600–Mutant Pediatric High-Grade Glioma},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {33},
  pages = {5174--5183},
  doi = {10.1200/jco.23.00558}
}
Kostenlos starten →